CervoMed appoints former McKinsey Senior Partner David Quigley to Board

CervoMed Inc.

David Quigley appointed to board effective Oct 27, 2025; board expanded from 7 to 8 members.
Quigley was McKinsey Senior Partner (2010-2025) leading Private Capital and Life Sciences practices.
Granted option to buy 16,200 shares at $7.02, vesting in 36 equal monthly installments.
Company expects FDA feedback on Phase 3 trial design for neflamapimod in DLB in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.